ClinicalTrials.gg
TerminatedNCT03661983Updated Mar 9, 2021Results posted

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

A Phase 4 interventional study of Aripiprazole and Placebo in Tourette's Disorder (TD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 42 sites in 3 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-03-09.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Lack of feasibility for completion of the trial within a reasonable time frame.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.

Enrollment
9th of 10
36 · median 97
Started
2018
with 1 other
Phase 4
2 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
6 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 4, and was the 10th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Tourette Syndrome as a file.
02

Study summary

To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).

Read the detailed description

This study will evaluate the long-term efficacy of oral aripiprazole in the treatment of pediatric participants with Tourette's Disorder (TD). The trial consists of 3 distinct phases: a pretreatment phase, open-label stabilization phase, and a double-blind randomized withdrawal phase.

03

Conditions studied

  • Tourette's Disorder (TD)

Browse trials for

Keywords

  • Aripiprazole
  • Tourette's Disorder
  • Pediatric
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is a male or female child or adolescent, 6 to 17 years of age (inclusive) at the time of signing the /assent.
  • The participant meets current 5th Edition (DSM-5) diagnostic criteria for TD, documented at screening and made by an adequately trained clinician, as confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version.
  • The participant has a Total Tic Score (TTS) ≥ 20 on the Yale Global Tic Severity Scale (YGTSS) at screening and baseline (Day 1).
  • The participant, a caregiver, and the investigator must all agree that the presenting tic symptoms cause impairment in the participant's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships.
  • Females of (all female participants ≥ 12 years of age and all female participants \< 12 years of age if menstruation has started) must have a negative pregnancy test and must not be pregnant or lactating.
  • Written informed consent must be obtained from the participant or a legally acceptable representative (eg, guardian or caregiver), in accordance with requirements of the trial site's institutional review board (IRB)/independent ethics committee (IEC) and local regulatory requirements, prior to the initiation of any protocol-required procedures. In addition, the participant, as required by the trial center's IRB/IEC, must provide informed assent at screening and as such must be able to understand that he or she can withdraw from the trial at any time.
  • Ability, in the opinion of the principal investigator, of the participant and the participant's legally acceptable representative (e.g., guardian) or caregiver(s) to understand the nature of the trial and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, and discontinuation of prohibited concomitant medications, to read and understand the written word in order to complete participant-reported outcomes measures, and to be reliably rated on assessment scales.

Exclusion criteria

Exclusion Criteria:

  • The participant presents with a clinical presentation and/or history that is consistent with another neurologic condition that may have accompanying abnormal movements. These include, but are not limited to, the following: Transient tic disorder; Huntington's disease; Parkinson's disease; Sydenham's chorea; Wilson's disease; Mental retardation; Pervasive developmental disorder; Tardive dyskinesia; Traumatic brain injury; Stroke; Restless legs syndrome.
  • The participant has a history of schizophrenia, bipolar disorder, or other psychotic disorder.
  • Participants who receive psychostimulants for the treatment of attention-deficit hyperactivity disorder (ADHD) and who have developed and/or had exacerbations of the tic disorder after the initiation of stimulant treatment. (Note that participants with ADHD who are treated with psychostimulants and have not developed new tics or a worsening of their current tics can be included if all other enrollment obligations are met).
  • The participant currently has a primary diagnosis that meets criteria for mood disorder.
  • The participant has severe obsessive-compulsive disease, as evidenced by a Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score > 16.
  • The participant has taken aripiprazole within 1 month (30 days) of the screening visit.
  • The participant has a history of neuroleptic malignant syndrome.
  • Participant is a sexually active male or female of (FOCBP) (all female participants ≥ 12 years of age and all female participants \< 12 years of age if menstruation has started) who will not agree to practice 2 acceptable methods of or who will not remain abstinent during the trial and for 30 or 90 days following the last dose of medicinal product (IMP) for females and males, respectively. Abstinence will be permitted if it is confirmed and documented at every trial visit.
  • The participant represents a significant risk of committing suicide based on history (suicide attempt in past 1 year).
  • The participant has a body weight \< 16 kg.
  • Participants who have taken neuroleptic or antiparkinson drugs within 14 days prior to baseline.
  • Participants requiring cognitive-behavioral therapy (CBT) for TD during the trial period. CBT for other nonexclusionary disorder must remain consistent through the trial.
  • The participant has met DSM-5 criteria for any significant psychoactive substance use disorder within the past 3 months.
  • A positive drug screen for cocaine, alcohol, or other drugs of abuse (excluding caffeine, nicotine, or prescribed psychostimulants for ADHD). Investigators can choose to repeat a positive drug screen one time during screening period after concurrence from the medical monitor. A second positive test for any drug of abuse would be exclusionary.
  • Participant requiring medication not allowed per protocol.
  • Use of any cytochrome P450 (CYP)2D6 and inhibitors or CYP3A4 inducers within 14 days prior to baseline and for the duration of the trial.
  • Other nutritional or dietary supplements and nonprescription herbal preparations for TD (eg, cannabinoids, N-acetylcysteine, omega-3 fatty acids, kava extracts, GABA supplements) within 7 days prior to baseline and for the duration of the trial, unless approved in advance by the medical monitor.
  • The inability to swallow tablets or tolerate oral medication.
  • Participant has participated in a clinical trial involving either study medication or interventional (non-medication) treatment for TD within the last 60 days.
  • The following laboratory test results, vital signs and (ECG) results are exclusionary: ≤ 75,000/mm\^3; ≤ 9 g/dL; Neutrophils, absolute ≤ 1000/mm\^3; > 3 × (ULN) as defined by the central laboratory; Alanine aminotransferase > 3 × ULN as defined by the central laboratory; Creatinine ≥ 2 mg/dL; Diastolic blood pressure > 105 mmHg; interval ≥ 450 msec (males) or ≥ 470 msec (females) using the corrected QT interval for heart rate using Fridericia's formula
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Open Label Stabilization Phase: Aripiprazole

    Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.

    Drug: Aripiprazole

  • Experimental
    Double Blind Phase: Aripiprazole Full Dose

    Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for \<50 kg participants,and 10 mg or 20 mg for \>50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.

    Drug: Aripiprazole

  • Experimental
    Double Blind Phase: Aripiprazole Half Dose

    Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for \<50 kg participants, and 5 mg or 10 mg for \>50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.

    Drug: Aripiprazole

  • Placebo comparator
    Double Blind Phase: Placebo

    Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.

    Drug: Placebo

Interventions

  • Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.

    Also known as: OPC-14597

  • DrugPlacebo

    Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase

    Relapse was defined as a loss of ≥ 50% of the improvement experienced during the open-label stabilization phase (i.e., improvement at the last assessment of Yale Global Tic Severity Scale (YGTSS) before randomization) on the Yale Global Tic Severity Scale Total Tic Score (YGTSS TTS). YGTSS provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic symptoms.

    Time frame: From Randomization up to 12 weeks in Double-blind Randomized Withdrawal Phase

07

Results

Posted Jan 22, 2021
Limitations and caveats
This trial was terminated early due to the withdrawal of post-marketing commitment (PMC) to FDA. The planned interim analysis was not conducted either.

Participant flow

Participants took part in the study at 13 investigative sites in Canada, the United States and Hungary from Oct 13, 2018 to Jun 30, 2020.

Open Label Stabilization Phase
Participant flow — Open Label Stabilization Phase
MilestoneOpen Label Stabilization Phase: AripiprazoleDouble Blind Phase: Aripiprazole Full DoseDouble Blind Phase: Aripiprazole Half DoseDouble Blind Phase: Placebo
Started36000
Completed25000
Not completed11000
Withdrew: Adverse event5000
Withdrew: Lack of efficacy1000
Withdrew: Withdrawal by parent/guardian2000
Withdrew: Study terminated by sponsor3000
Double-blind Randomized Phase
Participant flow — Double-blind Randomized Phase
MilestoneOpen Label Stabilization Phase: AripiprazoleDouble Blind Phase: Aripiprazole Full DoseDouble Blind Phase: Aripiprazole Half DoseDouble Blind Phase: Placebo
Started0988
Completed0770
Not completed0218
Withdrew: Adverse event0100
Withdrew: Disease relapse0006
Withdrew: Withdrawal by parent/guardian0001
Withdrew: Study terminated by sponsor0111

Outcome measures

PrimaryPercentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase

Relapse was defined as a loss of ≥ 50% of the improvement experienced during the open-label stabilization phase (i.e., improvement at the last assessment of Yale Global Tic Severity Scale (YGTSS) before randomization) on the Yale Global Tic Severity Scale Total Tic Score (YGTSS TTS). YGTSS provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic symptoms.

Time frame:
From Randomization up to 12 weeks in Double-blind Randomized Withdrawal Phase
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase
percentage of participantsDouble Blind Phase: Aripiprazole Full DoseDouble Blind Phase: Aripiprazole Half DoseDouble Blind Phase: Placebo
Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase0.00.075.0

Adverse events

Collected over From first dose up to 30 days after last dose of study drug (Up to approximately 36 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label Stabilization Phase: Aripiprazole0/36 (0%)0/36 (0%)17/36 (47.2%)
Double Blind Phase: Aripiprazole Full Dose0/9 (0%)1/9 (11.1%)3/9 (33.3%)
Double Blind Phase: Aripiprazole Half Dose0/8 (0%)0/8 (0%)3/8 (37.5%)
Double Blind Phase: Placebo0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent serious events
Most frequent serious events
EventOpen Label Stabilization Phase: AripiprazoleDouble Blind Phase: Aripiprazole Full DoseDouble Blind Phase: Aripiprazole Half DoseDouble Blind Phase: Placebo
Suicidal IdeationPsychiatric disorders0/361/90/80/8
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOpen Label Stabilization Phase: AripiprazoleDouble Blind Phase: Aripiprazole Full DoseDouble Blind Phase: Aripiprazole Half DoseDouble Blind Phase: Placebo
FatigueGeneral disorders7/360/90/80/8
SomnolenceNervous system disorders5/360/91/80/8
Pharyngitis streptococcalInfections and infestations0/360/91/80/8
Urinary tract infectionInfections and infestations0/360/91/80/8
Upper limb fractureInjury, poisoning and procedural complications0/360/91/80/8
AggressionPsychiatric disorders0/360/90/81/8
IrritabilityPsychiatric disorders1/360/90/81/8
RestlessnessPsychiatric disorders1/360/90/81/8
TachycardiaCardiac disorders1/361/90/80/8
Upper respiratory tract infectionInfections and infestations1/361/90/80/8

Baseline characteristics

The Enrolled Sample included all participants who entered the open-label stabilization phase.

Age, Continuous
Age, Continuous(years)Open Label Stabilization Phase: Aripiprazole
Mean10.9 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Stabilization Phase: Aripiprazole
Female6
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open Label Stabilization Phase: Aripiprazole
Hispanic or Latino7
Not Hispanic or Latino29
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label Stabilization Phase: Aripiprazole
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White32
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Open Label Stabilization Phase: Aripiprazole
Canada9
Hungary4
United States23
08

Study locations

42 sites
  • Advanced Research Center
    Anaheim, California 92805, United States
  • CT Trials - Riverside
    Riverside, California 92506, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Comprehensive Research Center
    Norwich, Connecticut 06360, United States
  • Sarkis Clinical
    Gainesville, Florida 32607, United States
  • Reliable Clinical Research
    Hialeah, Florida 33012, United States
  • Eastern Research
    Hialeah, Florida 33013, United States
  • Rothman Center for Pediatric Neuropsychiatry
    Saint Petersburg, Florida 33701, United States
  • Quest Pharmaceutical Services - Miami Research Associates
    South Miami, Florida 33143, United States
  • Pediatric and Adolescent Neurodevelopment Associates
    Atlanta, Georgia 30328, United States
  • Inova Clinical trials and Research Center
    Fayetteville, Georgia 30214, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • Neurobehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
  • Alivation
    Lincoln, Nebraska 68526, United States
  • The NeuroCognitive Institute
    Mount Arlington, New Jersey 07856, United States
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
  • Mood Disorders Consulting Medicine
    New York, New York 10036, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
  • Triangle Neuropsychiatry
    Durham, North Carolina 27707, United States
  • Quest Therapeutics of Avon Lake DBA Haidar Almhana Nieding
    Avon Lake, Ohio 44012, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Charak Center for Health and Wellness
    Garfield Heights, Ohio 44125, United States
  • North Star Medical Research
    Middleburg Heights, Ohio 44130, United States
  • IPS Research
    Oklahoma City, Oklahoma 73103, United States
  • ClinMed Research Associates, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Rivus Wellness and Research Institute
    Oklahoma City, Oklahoma 73112, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
  • Psychiatric Medical Associates
    Plano, Texas 75093, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Aspen Clinical Research - Orem
    Orem, Utah 84058, United States
  • University of Virginia School of Medicine
    Charlottesville, Virginia 22903, United States
  • Clinical Research Partners - Richmond
    Petersburg, Virginia 23805, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
  • Palouse Psychiatry & Behavioral Health
    Spokane, Washington 99202, United States
  • Kids Clinic
    Ajax, Ontario L1Z 0M1, Canada
  • Jodha Tishon Inc.
    Toronto, Ontario M6J 3S3, Canada
  • Vadaskert Alaptvany A Gyermekek Lelki Egeszsegeert
    Budapest, 1021, Hungary
  • Semmelweis Egyetem - I. sz. Gyermekgyógyászati Klinika
    Budapest, 1083, Hungary
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jun 2020, 20 months.

Results were first posted in Jan 2021, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2018
First posted
Sep 7, 2018
StartActual
Oct 13, 2018
Primary completionActual
Jun 30, 2020
CompletionActual
Jun 30, 2020
Results first posted
Jan 22, 2021
Last update
Mar 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03661983
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Oct 13, 2018
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020
Results posted
Jan 22, 2021
Last update
Mar 9, 2021

Study contacts

Eva Kohegyi, MD, MS
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion